Street View: Investors eye Gilead's year-end filing for HIV drug lenacapavir
** Gilead Sciences GILD.O reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for full-year earnings
** Gilead plans to file for U.S. regulatory approval of lenacapavir, a twice-yearly injection to prevent HIV infection, before the end of this year
** Shares rise 1.61% to $93.17 premarket
SETS SAIL FOR GROWTH
** Oppenheimer ("Outperform", PT $105) says change is in the air, with the company finally freeing itself from the shackles of some questionable business development and getting back to its roots as the innovator in antivirals
** Says Gilead 'sets sail for growth', adds lenacapavir has potential to transform prevention, improve adherence, and expand the PrEP market to new populations
** J.P.Morgan ("Overweight", PT $105) says Gilead remains on track for a launch for lenacapavir in PrEP in 2025, where brokerage expects relatively quick uptake
** BMO Capital Markets ("Outperform", PT $102) says the launch of liver disease treatment Livdelzi was another bright spot, co highlights early days outpacing internal expectations for patient demand
** RBC Capital Markets ("Sector Perform", PT $81) says data for cancer therapy anito-cel and HIV analyst day are key upcoming events, expectations likely high for both
Reporting by Sriparna Roy in Bengaluru
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
